646 related articles for article (PubMed ID: 31352980)
1. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
2. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
3. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
Chen X; Wood BL
Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
Kayser S; Walter RB; Stock W; Schlenk RF
Curr Hematol Malig Rep; 2015 Jun; 10(2):132-44. PubMed ID: 25994952
[TBL] [Abstract][Full Text] [Related]
5. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
6. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
8. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M; Freeman SD; Ossenkoppele GJ; Buccisano F; Hourigan CS; Ngai LL; Tettero JM; Bachas C; Baer C; Béné MC; Bücklein V; Czyz A; Denys B; Dillon R; Feuring-Buske M; Guzman ML; Haferlach T; Han L; Herzig JK; Jorgensen JL; Kern W; Konopleva MY; Lacombe F; Libura M; Majchrzak A; Maurillo L; Ofran Y; Philippe J; Plesa A; Preudhomme C; Ravandi F; Roumier C; Subklewe M; Thol F; van de Loosdrecht AA; van der Reijden BA; Venditti A; Wierzbowska A; Valk PJM; Wood BL; Walter RB; Thiede C; Döhner K; Roboz GJ; Cloos J
Blood; 2021 Dec; 138(26):2753-2767. PubMed ID: 34724563
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
Sun Y; Zhu G; Zhong H
Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613
[TBL] [Abstract][Full Text] [Related]
12. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
13. Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.
Schuurhuis GJ; Ossenkoppele GJ; Kelder A; Cloos J
Expert Rev Hematol; 2018 Dec; 11(12):921-935. PubMed ID: 30466339
[No Abstract] [Full Text] [Related]
14. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
15. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
Brooimans RA; van der Velden VHJ; Boeckx N; Slomp J; Preijers F; Te Marvelde JG; Van NM; Heijs A; Huys E; van der Holt B; de Greef GE; Kelder A; Schuurhuis GJ
Leuk Res; 2019 Jan; 76():39-47. PubMed ID: 30553189
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
Ehinger M; Pettersson L
APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
[TBL] [Abstract][Full Text] [Related]
19. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract][Full Text] [Related]
20. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them.
Li SQ; Chen M; Huang XY; Wang H; Chang YJ
Expert Rev Hematol; 2023; 16(12):981-990. PubMed ID: 37978882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
